BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics cash
Cash and short-term investments held at the end of each period.
BioXcel Therapeutics's cash was $12.84M at Jun 30, 2026. For fiscal 2025 it was $28.42M, down 4.8% from the year before. The highest annual figure on record is $232.97M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.42M | -4.8% |
| FY2024 | Dec 31, 2024 | $29.85M | -54.2% |
| FY2023 | Dec 31, 2023 | $65.22M | -66.3% |
| FY2022 | Dec 31, 2022 | $193.73M | -16.8% |
| FY2021 | Dec 31, 2021 | $232.97M | +9.3% |
| FY2020 | Dec 31, 2020 | $213.12M | +557.2% |
| FY2019 | Dec 31, 2019 | $32.43M | -23.8% |
| FY2018 | Dec 31, 2018 | $42.57M | +4698.8% |
| FY2017 | Dec 31, 2017 | $887.00K | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.84M | -26.3% |
| Q1 FY2026 | Mar 31, 2026 | $17.18M | -44.6% |
| Q4 FY2025 | Dec 31, 2025 | $28.42M | -4.8% |
| Q3 FY2025 | Sep 30, 2025 | $36.18M | -10.4% |
| Q2 FY2025 | Jun 30, 2025 | $17.44M | -69.0% |
| Q1 FY2025 | Mar 31, 2025 | $31.01M | -58.2% |
| Q4 FY2024 | Dec 31, 2024 | $29.85M | -54.2% |
| Q3 FY2024 | Sep 30, 2024 | $40.39M | -55.1% |
| Q2 FY2024 | Jun 30, 2024 | $56.27M | -55.9% |
| Q1 FY2024 | Mar 31, 2024 | $74.14M | -55.2% |
| Q4 FY2023 | Dec 31, 2023 | $65.22M | -66.3% |
| Q3 FY2023 | Sep 30, 2023 | $89.96M | -61.3% |
| Q2 FY2023 | Jun 30, 2023 | $127.55M | -45.4% |
| Q1 FY2023 | Mar 31, 2023 | $165.52M | -17.4% |
| Q4 FY2022 | Dec 31, 2022 | $193.73M | -16.8% |
| Q3 FY2022 | Sep 30, 2022 | $232.31M | -8.1% |
| Q2 FY2022 | Jun 30, 2022 | $233.45M | -14.5% |
| Q1 FY2022 | Mar 31, 2022 | $200.44M | +3.3% |
| Q4 FY2021 | Dec 31, 2021 | $232.97M | +9.3% |
| Q3 FY2021 | Sep 30, 2021 | $252.91M | +8.3% |
| Q2 FY2021 | Jun 30, 2021 | $273.06M | +316.9% |
| Q1 FY2021 | Mar 31, 2021 | $194.02M | +142.3% |
| Q4 FY2020 | Dec 31, 2020 | $213.12M | +557.2% |
| Q3 FY2020 | Sep 30, 2020 | $233.43M | +479.9% |
| Q2 FY2020 | Jun 30, 2020 | $65.50M | +118.6% |
| Q1 FY2020 | Mar 31, 2020 | $80.08M | +120.6% |
| Q4 FY2019 | Dec 31, 2019 | $32.43M | -23.8% |
| Q3 FY2019 | Sep 30, 2019 | $40.25M | -14.6% |
| Q2 FY2019 | Jun 30, 2019 | $29.97M | -40.5% |
| Q1 FY2019 | Mar 31, 2019 | $36.30M | -34.6% |
| Q4 FY2018 | Dec 31, 2018 | $42.57M | +4698.8% |
| Q3 FY2018 | Sep 30, 2018 | $47.12M | +6149.6% |
| Q2 FY2018 | Jun 30, 2018 | $50.35M | +17566.3% |
| Q1 FY2018 | Mar 31, 2018 | $55.47M | – |
| Q4 FY2017 | Dec 31, 2017 | $887.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $754.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $285.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
See a number that looks wrong?